News
Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering
-
Hopewell, New Jersey, May 12, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects, today announced the closing of its initial public offering (the “Offering”) of 3,375,000 shares of common stock at a public offering price of $4.00 per share. The shares began trading on the NYSE American on May 9, 2025, under the symbol “APUS.”05/12/2025
U.S. IPO Weekly Recap: Sizable Insurance IPOs Deliver Solid Trading
-
A few new issuers went public this past week, joined by two SPACs. Three IPOs are scheduled to list in the week ahead, although some small deals may join the calendar at the last minute. Street research is expected for three companies in the week ahead, and one lock-up period will be expiring.05/10/2025
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions
Is Apimeds Pharmaceuticals US, Inc (APUS) a buy, sell, or hold?
Apimeds Pharmaceuticals US, Inc (APUS) can sell. Click on Rating Page for detail.
What is Apimeds Pharmaceuticals US, Inc's stock price?
The price of Apimeds Pharmaceuticals US, Inc (APUS) is 1.73 and it was updated on 2025-06-26 11:00:32.
Is Apimeds Pharmaceuticals US, Inc (APUS) overvalued or undervalued?
Currently Apimeds Pharmaceuticals US, Inc (APUS) is in overvalued.
SEC Filings
Press Releases
| StockPrice Release |
|---|
APUS Ratings Summary
APUS Quant Ranking
